Peptides Corresponding to the Predicted Heptad Repeat 2 Domain of the Feline Coronavirus Spike Protein Are Potent Inhibitors of Viral Infection

Background Feline infectious peritonitis (FIP) is a lethal immune-mediated disease caused by feline coronavirus (FCoV). Currently, no therapy with proven efficacy is available. In searching for agents that may prove clinically effective against FCoV infection, five analogous overlapping peptides were designed and synthesized based on the putative heptad repeat 2 (HR2) sequence of the spike protein of FCoV, and the antiviral efficacy was evaluated. Methods Plaque reduction assay and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cytotoxicity assay were performed in this study. Peptides were selected using a plaque reduction assay to inhibit Feline coronavirus infection. Results The results demonstrated that peptide (FP5) at concentrations below 20 μM inhibited viral replication by up to 97%. The peptide (FP5) exhibiting the most effective antiviral effect was further combined with a known anti-viral agent, human interferon-α (IFN-α), and a significant synergistic antiviral effect was observed. Conclusion Our data suggest that the synthetic peptide FP5 could serve as a valuable addition to the current FIP prevention methods.

• Publication year

  2013

• Venue

  PLoS ONE

• Publication date

  2013-12-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1371/journal.pone.0082081PMID 24312629PMCID 3849439
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of Ebola Virus Entry by a C-peptide Targeted to Endosomes

  2011cited by this paper
• In vitro inhibition of feline coronavirus replication by small interfering RNAs

  2011cited by this paper
• Pathogenic characteristics of persistent feline enteric coronavirus infection in cats

  2010cited by this paper
• Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus

  2010cited by this paper
• Viral Entry Inhibitors Targeted to the Membrane Site of Action

  2010cited by this paper
• Current Peptide HIV Type-1 Fusion Inhibitors

  2009cited by this paper
• Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2015)

  2009cited by this paper
• A review of feline infectious peritonitis virus infection: 1963–2008

  2009cited by this paper
• Decline in human T-cell lymphotropic virus-1 prevalence in urban areas of Bissau, Guinea-Bissau: exploring the association with HIV infections

  2009cited by this paper
• Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2009)

  2009cited by this paper
• Isolation and identification of a novel feline coronavirus from a kitten with naturally occurring feline infectious peritonitis in Taiwan.

  2009cited by this paper
• Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors

  2008cited by this paper
• Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion Inhibitor*

  2008cited by this paper
• Treatment of cats with feline infectious peritonitis

  2008cited by this paper
• Differential role for low pH and cathepsin-mediated cleavage of the viral spike protein during entry of serotype II feline coronaviruses

  2008cited by this paper
• The carbohydrate-binding plant lectins and the non-peptidic antibiotic pradimicin A target the glycans of the coronavirus envelope glycoproteins

  2007cited by this paper
• Coronaviruses and their therapy

  2006cited by this paper
• Virus membrane-fusion proteins: more than one way to make a hairpin

  2006cited by this paper
• Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture

  2005cited by this paper
• IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW，Thompson RW，et al//Proc Natl Acad Sci U S A

  2005cited by this paper
• Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors

  2004cited by this paper
• Structural Basis for Coronavirus-mediated Membrane Fusion

  2004cited by this paper
• Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.

  2004cited by this paper
• Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein

  2004cited by this paper
• Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide.

  2003cited by this paper
• The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex

  2003cited by this paper
• The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults

  2002cited by this paper
• C-Terminal gp40 Peptide Analogs Inhibit Feline Immunodeficiency Virus: Cell Fusion and Virus Spread

  2002cited by this paper
• Mechanisms of viral membrane fusion and its inhibition.

  2001cited by this paper
• Protein Design of an HIV-1 Entry Inhibitor

  2001cited by this paper
• Functional Importance of the Coiled-Coil of the Ebola Virus Glycoprotein

  2000cited by this paper
• Attacking AIDS with a 'cocktail' therapy?

  1999cited by this paper
• Structural basis for membrane fusion by enveloped viruses.

  1999cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

  1998cited by this paper
• Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

  1998cited by this paper
• Two Amino Acid Changes at the N-Terminus of Transmissible Gastroenteritis Coronavirus Spike Protein Result in the Loss of Enteric Tropism

  1997cited by this paper
• Placebo-controlled evaluation of a modified life virus vaccine against feline infectious peritonitis: safety and efficacy under field conditions

  1997cited by this paper
• Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion.

  1996cited by this paper
• Time to hit HIV, early and hard.

  1995cited by this paper
• Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

  1994cited by this paper
• Toxicologic effects of ribavirin in cats

  1993cited by this paper
• HIV-1 inhibition by a peptide

  1993cited by this paper
• Inhibitory effects of ribavirin alone or combined with human alpha interferon on feline infectious peritonitis virus replication in vitro☆

  1989cited by this paper
• Inhibition of feline infectious peritonitis virus replication by recombinant human leukocyte (alpha) interferon and feline fibroblastic (beta) interferon.

  1988cited by this paper
• Infection studies in kittens, using feline infectious peritonitis virus propagated in cell culture.

  1981cited by this paper

• Identification and evaluation of Nordihydroguaiaretic acid (NDGA) as an active traditional Chinese medicine compound inhibiting the 3C-like protease of feline infectious peritonitis virus.

  2025cites this paper
• Feline Infectious Peritonitis: European Advisory Board on Cat Diseases Guidelines

  2023cites this paper
• A database of anti-coronavirus peptides

  2022cites this paper
• Known Cellular and Receptor Interactions of Animal and Human Coronaviruses: A Review

  2022cites this paper
• Surface Display of Peptides Corresponding to the Heptad Repeat 2 Domain of the Feline Enteric Coronavirus Spike Protein on Bacillus subtilis Spores Elicits Protective Immune Responses Against Homologous Infection in a Feline Aminopeptidase-N-Transduced Mouse Model

  2022cites this paper
• Animal Coronavirus Diseases: Parallels with COVID-19 in Humans

  2021cites this paper
• Antiviral peptides against Coronaviridae family: A review

  2021cites this paper
• Feline Coronavirus Antivirals: A Review

  2021cites this paper
• Performance and Capacity Evaluation of the Spanish Health System in SARS-CoV-2 Pandemic

  2020influential citation
• Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus

  2020influential citation
• COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles’ heel conserved region to minimize probability of escape mutations and drug resistance

  2020cites this paper
• The use of knowledge management tools in viroinformatics. Example study of a highly conserved sequence motif in Nsp3 of SARS-CoV-2 as a therapeutic target

  2020cites this paper
• Drawing Comparisons between SARS-CoV-2 and the Animal Coronaviruses

  2020cites this paper
• Lipidation increases antiviral activities of coronavirus fusion-inhibiting peptides

  2017cites this paper
• Nanoparticulate vacuolar ATPase blocker exhibits potent host-targeted antiviral activity against feline coronavirus

  2017cites this paper
• Identification of a peptide derived from the heptad repeat 2 region of the porcine epidemic diarrhea virus (PEDV) spike glycoprotein that is capable of suppressing PEDV entry and inducing neutralizing antibodies

  2017cites this paper
• Identification of the peptide derived from S1 domain that inhibits type I and type II feline infectious peritonitis virus infection

  2015cites this paper
• Update on Antiviral Therapies

  2015cites this paper
• An update on feline infectious peritonitis: Diagnostics and therapeutics

  2014cites this paper
• Synthesis and anti-influenza virus activity of 4-oxo- or thioxo-4,5-dihydrofuro[3,4-c]pyridin-3(1H)-ones

  2014cites this paper